-
-
-
-
-
-
Viral cancer therapy - 26/10/2022
Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.
https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
-
-
-
Organ-on-chip for the analysis of drug effects - 20/07/2022
Organ-on-chips systems are systems containing miniature tissues grown inside mircrofluidic chips. By integrating microsensors, researchers at the IMTEK Freiburg, together with the RWTH Aachen University Hospital, created a novel variant that allows the measurement of metabolic activity directly on site and in real time. This enables the rapid and detailed analysis of drug effects outside an organism.
https://www.gesundheitsindustrie-bw.de/en/article/news/new-3d-cell-platform-allows-continuous-metabolic-monitoring
-
-
-
Press release - 13/01/2022
Making important raw materials for fine chemicals out of carbon dioxide really works. As part of the Max Planck collaborative project eBioCO2n, a team of researchers from Fraunhofer IGB have successfully performed a first ever fixation of CO2 via a multi-enzyme enzyme reaction driven by electricity yielding a prospective intermediate for the chemical industry. The process for electro-biocatalytic CO2 fixation was recently published and is…
https://www.biooekonomie-bw.de/en/articles/pm/turning-harmful-co2-useful-chemicals
-
-
Press release - 13/10/2021
EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
-
-
-
Press release - 02/08/2021
Carbon dioxide is one of the main drivers of climate change – which means that we need to reduce CO2 emissions in the future. Fraunhofer researchers are highlighting a possible way to lower these emissions: They use the greenhouse gas as a raw material, for instance to produce plastics. To do this, they first produce methanol and formic acid from CO2, which they convert via microorganisms into building blocks for polymers and the like.
https://www.biooekonomie-bw.de/en/articles/pm/co2-raw-material-plastics-and-other-products
-
Press release - 06/07/2021
Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
-
Start-up kernique catch the zeitgeist - 29/06/2021
A delicious vegan nut snack that uses no sugar, artificial additives, gluten or palm oil, is full of essential nutrients, and is part of a commitment to environmental and social sustainability. Impossible? An Esslingen-based start-up called kernique proves otherwise. The start-up is currently planning a crowdfunding phase that offers a lucrative deal for investors. The idea catches the zeitgeist, but what exactly makes it stand out?
https://www.biooekonomie-bw.de/en/articles/news/nut-snack-sustainable-ecological-concept
-
-
Press release - 24/03/2021
Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…
https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
-
-
-
-
Website address: https://www.biooekonomie-bw.de/en/search